Figure 1.

Functional assays to determine whether monoclonal antibodies (mAb) 4G2, 7D4 and 10B6 inhibit complement in different species. (a–e) Classical pathway haemolysis (CH50). Sera tested were human (a), rat (b), rabbit (c), guinea pig (d) and mouse (e). Commercial mAb RO7112689 and Eculizumab were used as comparators. (f) Calculation of 50% inhibitory dose showed that human C5 inhibition by mAb 10B6 was equivalent to the two comparator mAb, RO7112689 and Eculizumab, and that 4G2 and 7D4 strongly inhibited rat C5. (g, h) Alternative pathway (AP) haemolysis (AH₅₀) assay using human (g) and rat (h) serum; all tested mAb inhibited AP in human serum, while 4G2 and 7D4 inhibited rat AP. (i) Inhibition of C5a generation by the novel mAb in a classical pathway assay with human serum; all three mAb efficiently inhibited C5a generation in a dose‐dependent manner. All experiments were repeated three times with the same results. The error bars are standard errors of triplicates. The dashed lines correspond to the comparator mAb.